Cochrane · systematic review · CD009096
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
Li, ECK, Heran, BS, Wright, JM · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
All angiotensin converting enzyme (ACE) inhibitors versus all angiotensin receptor blockers (ARBs) for primary hypertension
Population: people with primary hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality All angiotensin converting enzyme (ACE) inhibitors vs all angiotensin receptor blockers (ARBs) | RR 0.98 [0.88, 1.1] | 5 studies · 10248 participants | Moderate |
Total cardiovascular events All angiotensin converting enzyme (ACE) inhibitors vs all angiotensin receptor blockers (ARBs) | RR 1.07 [0.96, 1.19] | 3 studies · 5499 participants | Low |
Withdrawal due to adverse effects All angiotensin converting enzyme (ACE) inhibitors vs all angiotensin receptor blockers (ARBs) | RR 0.83 [0.74, 0.93] | 8 studies · 10963 participants | High |